The American Cancer Society tracks survival rates for 22 types of localized cancer, including the most common in the US: prostate (100%), skin (99.6% five-year survival rate), breast (99.3%), lung (65 ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Swiss pharma giant Roche today released financial results for the first nine months of 2025, showing that group sales grew by ...

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® ...

A Fermanagh woman says a routine breast cancer screening at the Lakeland Forum may have saved her life, after it revealed a tumour she would ...

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 14.9 billion for the third quarter of 2025, up 6% year over ...

For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

Listening to stories of other breast cancer survivors gave Vanessa Pontes hope for her own treatment and future ...

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing ...